Eli Lilly will report first quarter earnings before the bell. Here's what Wall Street expects

David Ricks, chief executive officer of Eli Lilly & Co., at the Semafor World Economy Summit during the International Monetary Fund (IMF) and World Bank Spring meetings in Washington, DC, US, on Friday, April 17, 2026. Aaron Schwartz | Bloomberg | Eli Lilly is slated to report first-quarter earnings before the bell on Thursday, in one of the most closely watched reports across the healthcare sector. Here's what Wall Street is expecting, based on a survey of analysts by LSEG: Earnings per share: $6.66 adjusted expected Revenue: $17.62 billion expected Demand for the company's blockbuster obesity drug Zepbound and diabetes counterpart Mounjaro has helped fuel several solid quarters for Lilly, which holds the majority market share in the booming GLP-1 space. Analysts expect Zepbound to rake in overall sales of $4.04 billion, with $3.98 billion coming from the U.S., according to StreetAccount estimates. Meanwhile, they expect Mounjaro to book worldwide sales of $7.26 billion, including U.S. revenue of $3.87 billion, StreetAccount estimates said. The company's newly approved GLP-1 pill for obesity, Foundayo, launched in the second quarter, so its sales won't be included in Thursday's report. Still, the pill's rollout is likely to dominate the discussion during Lilly's first-quarter earnings call. …